Table 2.
Statistical properties and characteristics of CROMs and PROMs
| EASI | SCORAD | oSCORAD | PO-SCORAD | ADCT | RECAP | POEM | DLQI | Skindex29 | |
|---|---|---|---|---|---|---|---|---|---|
| Construction and validation | |||||||||
| Inter observed evaluation | + + + | + + + | + + + | + + + | + | + | + + + | // | // |
| Intra-observed evaluation | + + + | + + + | + + + | + + + | + | + | + + + | // | // |
| Reliability | + + + | + + + | + + + | + + + | + | + | + + + | // | // |
| Internal validation | + + + | + + + | + + | + + + | + | + | + + + | // | // |
| Internal consistency | + + + | + + + | + + | + + + | + | + | + + + | // | // |
| Interpretability | + + + | + + + | + + | + + + | + | – | + + + | // | // |
| Acceptability | + + + | + + + | + + | + + | + | – | + + + | // | // |
| Minimal clinically significant difference | + /6.6 | + /8.7 | + /8.2 | + /8.2 | + /5 | – | + + /3.4 | // | // |
| External validation | + + | + + | + | + | + | + | + + | // | // |
| Minimum and maximum score | 0–72 | 0–103 | 83// | 0–103.6 | 0–24 | 28 | 28 | ||
| Targeted population and applicability | |||||||||
| Age | Any age+ | Any age+ | Any age+ | Any age | > 18 years | Any age+ | Any age+ | // | // |
| Current usage | C/T | C/T | C/T | // | T | T | C/T | // | // |
| Spanish translation | Yes | Yes | Yes | Yes | Yes | No | Yes | // | // |
| Portuguese translation | Yes | Yes | Yes | Yes | Yes | No | Yes | // | // |
| Language validation in Latin America | No | No | No | No | No | No | No | // | // |
| External validation in LA | No | No | No | No | No | No | No | // | // |
| Accessibility | Yes | Yes | Yes | Yes | Yes | Yes | Yes | // | // |
| Utility | Yes | Yes | Yes | Yes | Yes | Yes | Yes | // | // |
| Time to implement | < 10 min* | < 10 min* | < 10 min* | < 10 min* | < 10 min* | < 10 min* | < 10 min* | // | // |
| Patient perspective | No | Yes | No | Yes | Yes | Yes | Yes | // | // |
| Easy for physician | Yes* | Yes* | Yes* | No | Yes* | Yes* | Yes* | // | // |
| Easy for patient | Yes* | Yes* | Yes* | No | Yes* | Yes* | Yes* | // | // |
| When to implement | B/F | B/F | B/F | B/F | B/F | B/F | B/F | // | // |
| Time range analyzed | Present | Present | Present | Present | 7 days | 7 days | 7 days | // | // |
| Strengths | Extent of affected skin | Several domains | Simplicity/ > specificity | Duality (CROM/PROM) | Simplicity | Simplicity | Simplicity | ||
| Limitations | MDA | Complexity*/ < specificity | Purely objective | < acceptability | Only for adults | Not in Spanish or Portuguese | No mood eval | ||
 | |||||||||
+ + +: evaluated in at least two centers other than where the scale was constructed. + +: evaluated in one center other than where the scale was constructed. +: evaluated in the same center where the scale was constructed. –: no information. * depends on whether technological tools are available. C/R: clinical practice and trials. B/F: Baseline and follow-up. +: Most of the studies in children > 2 years old. //: additional points for severe disfiguring eczema of the face and hands